地西他滨与阿糖胞苷为基本的低剂量化疗方案运用于老年急性髓系白血病的临床分析  

Clinical Analysis of Descitabine and Cytosine Arabinoside as a Basic Low-dose Chemotherapy Regimen in Elderly Patients with Acute Myeloid Leukemia

作　　者：侯艳秋 HOUYan-qiu(Hulunbeir People’s Hospital,Hulunbeir 021008,China)

机构地区：[1]呼伦贝尔市人民医院,内蒙古呼伦贝尔021008

出　　处：《中国医药指南》2020年第19期127-128,共2页Guide of China Medicine

摘　　要：目的探析地西他滨联合阿糖胞苷为基本的低剂量化疗方案运用于老年机械髓系白血病的临床疗效。方法采集2018年1月至2019年1月在我院接受治疗的老年急性髓系白血病患者共68例,结合本次治疗方案划分成参照组(低剂量阿糖胞苷)联合组(地西他滨联合阿糖胞苷低剂量),各组为34例,分析两组患者用治疗前、后的免疫细胞变化、不良反应及临床有效率情况。结果联合组治疗后免疫细胞各指标变化情况,均较治疗前显著改善,则显著优于参照组,差异有统计学意义(P <0.05);联合组治疗后出现感染、出血、肝功能损伤及心脏毒性不良反应发生率情况,均较低于参照组,差异有统计学意义(P <0.05)联合组获得的临床总有效率为32例(94.12%),显著高于参照组获得的临床总有效率的24例(70.59%),差异有统计学意义(P <0.05)。结论地西他滨联合阿糖胞苷为基本的低剂量化疗方案运用于老年急性髓系白血病的临床效果确切,值得临床推广。Objective To explore the clinical efficacy of descitabine combined with cytarabine as a basic low-dose chemotherapy regimen in elderly patients with mechanical myeloid leukemia.Methods 68 elderly patients with acute myeloid leukemia who were treated in our hospital from January 2018 to January 2019 were collected.Combined with this treatment plan,they were divided into reference group(low dose cytarabine)combined group(desetabine combined with cytarabine low dose),34 cases in each group.The changes of immune cells before and after treatment in the two groups were analyzed.Adverse reactions and clinical efficacy.Results After treatment,the changes of immune cell indexes in the combined group were significantly improved compared with those before treatment,and the difference was significantly better than that in the control group(P<0.05).The incidence of infection,bleeding,liver injury and adverse cardiac reaction after treatment in the combined group was lower than that in the control group(P<0.01),and there was a significant difference between the two groups(P<0.05).The total clinical effective rate of the combined group was 32 cases(94.12%),which was significantly higher than that of the control group 24 cases(70.59%).The difference was statistically significant(P<0.05).Conclusion Descitabine combined with cytarabine is a basic low-dose chemotherapy regimen for the elderly patients with acute myeloid leukemia.

关 键 词：地西他滨 阿糖胞苷 老年急性髓系白血病 不良反应 

分 类 号：R733.7[医药卫生—肿瘤]